CaroGen Corporation, a Hamden, CT-based biotechnology company, raised $150k in funding.
Connecticut Innovations provided the funding via its Pre-Seed Fund.
The company intends to use the funds to grow operations in Hamden.
Led by Bijan Almassian, Ph.D., Co-Founder, Chairman and CEO, Valerian Nakaar, Ph.D., Co-Founder and Vice President, Research & Development, and Marc Silver, CBO, CaroGen provides a platform technology for generating vaccines, which is based on replication-proficient, virus-like vesicles (rVLVs) allowing target antigens to accumulate in high levels in cells, thereby amplifying specific immune responses and creating more potent immune therapies.
The company, which has licensed its core technology from Yale University, will focus initially on a treatment for patients with chronic hepatitis B infections.